Welcome to BioSeeker Group!

Triple Analysis: Pancreatic Cancer, Prostate Cancer and Apoptosis

Additional Information

Published Date Sep 12, 2012
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 4213
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Pancreatic Cancer, Prostate Cancer and Apoptosis in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Apoptosis.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Prostate Cancer and Apoptosis.

    To find out more about Triple Analysis: Pancreatic Cancer, Prostate Cancer and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Prostate Cancer and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in both Pancreatic Cancer and Prostate Cancer and by the mechanism/target/effect of Apoptosis. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Prostate Cancer
The prostate cancer drug report part comprises defined and up to date development strategies for 394 drugs within the portfolio of 222 companies world-wide, from Ceased to Marketed. The report extensively analyses their 227 identified drug targets, organized into 216 drug target strategies, and assesses them in breast cancer drug development.
This part is based on the following publication:
Competitive Handbook towards Personalized Medicine in Prostate Cancer

Part III: Apoptosis
The apoptotic cancer drug report part comprises defined and up to date development strategies for 234 drugs in oncology within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 157 drug target strategies, and assesses them in 69 cancer indications.
This part is based on the following publication:
Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part II: Prostate Cancer
5.1 The Scope of this Report 31
6 Consider the Therapeutic Target Among Prostate Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (227 Drug Targets) 35-437
7 Emerging New Products to Established Ones: Drug Target Strategies of Prostate Cancer Drugs by their Highest Stage of Development (216 Drug Target Strategies and 394 Drugs) 438-699
8 Compound Strategies at Work: Competitive Benchmarking of Prostate Cancer Drugs by Compound Strategy (8 Compound Strategies) 700-748
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Prostate Cancer Drug Pipeline by Investigator (222 Investigators and 394 Drugs) 749-1470
10 Disclaimer 1471
Figures: Includes 8 Figures
Tables: Includes 283 Tables
Total Number of Pages: 1,493

Part III: Apoptosis
5.1 The Scope of this Report 33
6 Consider the Therapeutic Target Among Apoptotic Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (181 Drug Targets) 37-416
7 Emerging New Products to Established Ones: Drug Target Strategies of Apoptotic Drugs in Oncology by their Highest Stage of Development (157 Drug Target Strategies and 234 Drugs) 417-622
8 Compound Strategies at Work: Competitive Benchmarking of Apoptotic Cancer Drugs by Compound Strategy(7 Compound Strategies) 623-660
9 Selecting Indication for Apoptotic Drugs in Oncology (69 Cancer Indications) 661-776
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Apoptotic Drug Pipeline in Oncology by Investigator (158 Investigators and 234 Drugs) 777-1601
Disclaimer 1602
11 Drug Index 1603
12 Company Index 1611
Figures: Includes 7 Figures
Tables: Includes 315 Tables
Total Number of Pages: 1,617

This Report Includes the Following Companies:
AB Science
Abbott
Access
Active Biotech
Advanced Life Sciences
Advantagene
Advaxis
AEgera
AEterna Zentaris
Aida Pharmaceuticals
Aileron Therapeutics
Alchemia
Alethia Biotherapeutics
Allos Therapeutics
Alnylam
AlphaVax
Alseres Pharmaceuticals
Altor BioScience
Ambrilia Biopharma
American Gene Technology International
Amgen
Anadys Pharmaceuticals
Anaphore
Anavex Life Sciences
AndroBioSys
Antisense Pharma
Antisense Therapeutics
Antisoma
Anza Therapeutics
Aphios
Apogee Biotechnology
Apogenix
ApopLogic Pharmaceuticals
Apotex
Aprea
Ardana
Ardea Biosciences
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Ascenta Therapeutics
Ascepion Pharmaceuticals
Astellas
Astex Pharmaceuticals
Astex Therapeutics
AstraZeneca
Attenuon
AVEO
AVI BioPharma
Avila Therapeutics
Basilea Pharmaceutica
Bavarian Nordic
Baxter International
Bayer
Bellicum Pharmaceuticals
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Bioenvision
Biogen Idec
BioInvent
BioLineRx
BioMarin
Biomas
BioNetWorks
Bionovo
BioNumerik
BioSante
Biostar
BioVex
Boehringer Ingelheim
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Camurus
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Cel-Sci
Celera
Celgene
Cell Therapeutics
Celldex Therapeutics
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
Chlorogen
Chroma Therapeutics
Circadian Technologies
Cleveland BioLabs
Colby
CombinatoRx
CompleGen
Cornerstone Pharmaceuticals
Coronado Biosciences
Cosmo Bioscience
Critical Outcome Technologies
CritiTech
Curaxis
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daewoong
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Debiopharm
Dendreon
DeveloGen
Dongkook Pharm
ECI
EGEN Inc
Eisai
Eleos
Eli Lilly
Emergent BioSolutions
Endo Pharmaceuticals
Endocyte
Ensemble Discovery
EntreMed
Epeius Biotechnologies
EpiCept
Erimos
Esperance Pharmaceuticals
Etubics
EUSA Pharma
Exelixis
Ferring
FibroGen
Formula Pharmaceuticals
Galectin Therapeutics
Galena Biopharma
Gemin X Pharmaceuticals
Generex
GENova Biotherapeutics
Genovax
Genta
GenVec
Gerolymatos
Geron
Gilead Sciences
GlaxoSmithKline
GlycoGenesys
Glycotope
Got-a-Gene
GP Pharm
GPC Biotech
Green Cross
GTx
Harbor BioSciences
Hoffmann-La Roche
Human Genome Sciences
Idera Pharmaceuticals
IGF Oncology
ImmunoCellular Therapeutics
Immunocore
ImmunoGen
Immunomedics
ImmuPharma
Immutep
Incyte Corporation
Infinity Pharmaceuticals
Innate Pharma
InNexus Biotechnology
Innovive
Inovio
Insmed
Insys Therapeutics
Intradigm
Introgen Therapeutics
Ipsen
Isis Pharmaceuticals
ISU ABXIS
Ivy Medical Chemicals
Johnson & Johnson
Kadmon
Kalypsys
Karo Bio
Keryx Biopharmaceuticals
Kinex
Kyowa Hakko Kirin
Leo
Ligand
Lorus Therapeutics
Mannkind
Marillion Pharmaceuticals
MBiotec
Med Discovery
Meda
Medarex
MediGene
MedImmune
Mediolanum
Medisyn Technologies
Medivation
Menarini
Merck & Co
Merck KGaA
Merrimack
Merrion Pharmaceuticals
Mersana Therapeutics
MethylGene
Micromet
Mojave Therapeutics
Molecular Insight
Nektar Therapeutics
Nereus Pharmaceuticals
Nerviano Medical Sciences
Neurocrine Biosciences
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
Novelix
Novogen
Oasmia
OncoGenex Pharmaceuticals
OncoMed
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Orion Pharma
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Pantarhei Bioscience
Patrys
Pepscan Therapeutics
Pfizer
Pharmacyclics
PharmaGap
PharmaMar
Pharmexa
Pharminox
Philogen
Pierre Fabre
Piramal
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
ProNAi Therapeutics
ProStrakan
Protgen
Q Chip
QLT
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
RESprotect
Rexahn
Rigel
Rosetta Genomics
Rottapharm Madaus
Salzburg Therapeutics
Samyang
Sanofi
Santaris Pharma
Sapphire Therapeutics
SBI Biotech
SBIO
Seattle Genetics
SeleXel
Semafore Pharmaceuticals
Senesco Technologies
Serometrix
SGX Pharmaceuticals
Shire
Siena Biotech
Sigma-Tau
Soligenix
Sophiris Bio
SRI International
SuperGen
Supratek Pharma
Switch Pharma
SymBio Pharmaceuticals
Symbiotec
Synta Pharmaceuticals
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
Tau Therapeutics
Taxolog
Telik
TetraLogic Pharmaceuticals
Teva
Thallion Pharmaceuticals
Therion Biologics
Tigris Pharmaceuticals
Titan Pharmaceuticals
Tokai Pharmaceuticals
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trion Pharma
Twinstrand Therapeutics
UMN Pharma
Unigene
United Biomedical
ValiRx
Vaxon Biotech
VaxOnco
VBL Therapeutics
Velacor Therapeutics
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Viralytics
ViroMed
ViroTarg
VM Discovery
Xerion
Xoma
Yakult Honsha
YM BioSciences
Zeria
Zydus Cadila
A Shortlist of Drugs Included are:
131I-tositumomab
abarelix
abiraterone acetate
adecatumumab
aderbasib
AEG-35156
AEZS-108
afatinib
aflibercept
AGS-1C4D4
ALT-801
alvocidib
AME-133
amonafide dihydrochloride
amonafide malate
APC-100
APG-101
APR-246
apricoxib
ARC-100
ARQ-197
AS-101
AS-1411
atrasentan
AVX-701
bafetinib
bardoxolone methyl
belinostat
bevacizumab
BIBF-1120
bicalutamide
BMS-777607
BMS-936558
bortezomib
bosutinib
BP-GMAX-CD1
brivanib alaninate
brivudine
buserelin
BZL-101
Cabozantinib
canfosfamide hydrochloride
capecitabine
carlumab
catumaxomab
cediranib
celecoxib
cenersen
cetuximab
CG-201
cilengitide
cintredekin besudotox
cixutumumab
conatumumab
CPI-613
CRLX-101
crolibulin
custirsen
dalotuzumab
danusertib
dasatinib
DCVax-prostate
degarelix
denosumab
deslorelin
DI-17E6
dinaciclib
docetaxel
dovitinib lactate
doxercalciferol
doxorubicin
dulanermin
dutasteride
E-75
E-7820
eniluracil
entinostat
enzastaurin hydrochloride
erlotinib
estramustine phosphate sodium
ethinyl estradiol sulfonate
everolimus
figitumumab
flutamide
fosbretabulin tromethamine
fulvestrant
ganitumab
gataparsen
GDC-0980
gefitinib
goserelin
GSK-1120212
GT-111
GTx-758
GV-1001
GVAX
GVX-3322
GX-301
HE-3235
histrelin
ibritumomab tiuxetan
icotinib hydrochloride
idronoxil
imatinib mesilate
imetelstat
IMP-321
inecalcitol
INSM-18
interleukins
intetumumab
ipilimumab
irinotecan
irinotecan hydrochloride
irosustat
ispinesib mesylate
kahalalide F
KD032
KX2-391
L19-IL2
lapatinib ditosylate
lestaurtinib
leucine-doxorubicin
leuprolide
leuprolide acetate
leuprorelin
leuprorelin acetate
LIP-131I
LipoVIL12
litronesib
lonaprisan
LOR-2040
LOR-2501
lumiliximab
LY-2275796
mapatumumab
masitinib
MCS-110
MDV-3100
MetXia
MKC-1
MLN-8237
mocetinostat
motexafin gadolinium
Nab-docetaxel
nadroparin
navitoclax
nilutamide
nimotuzumab
noscapine
obinutuzumab
oblimersen sodium
OGX-427
olaparib
olaratumab
ON-01910
Oncohist
orteronel
OTS-102
ozarelix
P-276-00
paclitaxel
paclitaxel polyglumex
PancAtak
panitumumab
panobinostat
pasireotide
pasireotide LAR
PAT-SC1
pazopanib hydrochloride
PBI-1402
PCI-24781
PCI-27483
pemetrexed disodium
pentamidine isethionate
perifosine
pertuzumab
plitidepsin
PLX-3397
ProstAtak
PROSTVAC
PRX-302
PX-12
PX-866
quarfloxacin
quinacrine
R-(-)-gossypol
RAF-265
ramucirumab
retaspimycin
Rexin-G
ridaforolimus
rilotumumab
romidepsin
ruxolitinib
RX-0201
sagopilone
sargramostim
SB-939
seliciclib
selumetinib
siltuximab
sipuleucel-T
sorafenib tosylate
SPC-2996
ß-lapachone
SU-6668
sunitinib malate
TAK-448
talminogene laherparepvec
tandutinib
tasquinimod
tegafur + uracil
temsirolimus
Tenarad
terameprocol
tigapotide triflutate
tigatuzumab
tipifarnib
TL-32711
tocilizumab
TOK-001
toremifene citrate
trabedersen
trastuzumab
TRC-105
tremelimumab
triciribine phosphate
trilostane
triptorelin
TroVax
TRU-016
TS-1
tucotuzumab celmoleukin
vandetanib
varlitinib
vismodegib
volasertib
volociximab
vosaroxin
WX-671
XL-147
XL-647
YM-155
Z-360
zibotentan

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Prostate Cancer and Apoptosis.
    To find out more about Triple Analysis: Pancreatic Cancer, Prostate Cancer and Apoptosis, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Prostate Cancer and Apoptosis is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Colorectal Cancer, Angiogenesis and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Learn More


Triple Analysis: Lymphoma, Melanoma and Peptides
This triple analysis focuses on cancer drug development strategies in both Lymphoma and Melanoma and by the compound strategy of Peptides. Learn More

Other selected research from the 'Oncology' category:


Breast Cancer Drug Pathway Analyzer
There are today at least 745 targeted molecular therapies known to affect more than 262 specific intracellular signaling pathways for the treatment of breast cancer. The rational for this plethora of treatment strategies is based on our increasing understanding of the 377 drug targets that are included in this drug-pathway analyzing tool. No less than 358 of these have been recorded with mutations and 63 drug targets have mutations which have been causally implicated in cancer. Learn More


Triple Analysis: Lung Cancer, Protein Kinase Inhibitors and Peptides
This triple analysis focuses on cancer drug development strategies in one specific cancer indication (Lung Cancer), one mechanism/target/effect area (Protein Kinase Inhibitors) and one compound specific area (Peptides). Learn More